GlobeNewswire: Nascent Biotech, Inc. Contains the last 10 of 9 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T21:33:13ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/02/05/1980399/0/en/Nascent-Biotech-Inc-CEO-Interviewed-by-The-Wall-Street-Analyzer.html?f=22&fvtc=4&fvtv=52156Nascent Biotech, Inc. CEO Interviewed by The Wall Street Analyzer2020-02-05T15:44:11Z<![CDATA[San Diego, CA, Feb. 05, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO) is pleased to release a recent interview with company President | CEO Sean Carrick, on The Wall Street Analyzer, a multi-media financial research and publishing company reporting to the investment community on publicly held companies. It can be heard in full at: https://wallstreetanalyzer.com/2020/02/04/nascent-biotech-inc-otcqb-nbio-sean-carrick-president-and-ceo/]]>https://www.globenewswire.com/news-release/2020/01/30/1977628/0/en/Nascent-Biotech-Founder-Dr-Mark-Glassy-Will-Present-at-the-Clinical-Operation-in-Oncology-Trials-Meeting-in-San-Diego-in-February.html?f=22&fvtc=4&fvtv=52156Nascent Biotech Founder, Dr. Mark Glassy, Will Present at the Clinical Operation in Oncology Trials Meeting, in San Diego in February2020-01-30T15:00:00Z<![CDATA[SAN DIEGO, CA , Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nascent Biotech, Inc. (OTCQB: NBIO) founder Dr. Mark C. Glassy will be presenting on “Navigating the Unique Challenges Presented in Immune Oncology trials” in San Diego on February 12th. The meeting will be attended by influential leaders in the Pharmaceutical and Investment community.]]>https://www.globenewswire.com/news-release/2020/01/15/1970930/0/en/Nascent-Biotech-Inc-Featured-in-New-Research-Update.html?f=22&fvtc=4&fvtv=52156Nascent Biotech, Inc. Featured in New Research Update2020-01-15T15:04:14Z<![CDATA[San Diego, CA, Jan. 15, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO), an emerging biotech company, with IND Clearance and IRB approval to begin Clinical trials for Brain Cancer, is very pleased to announce that Marble Arch Research Inc., a leading independent equity research provider, has produced a new investment research report on the Company.]]>https://www.globenewswire.com/news-release/2019/09/11/1914118/0/en/Nascent-Biotech-Receives-One-Million-Dollar-Commitment-From-TRITON-FUNDS-LP.html?f=22&fvtc=4&fvtv=52156Nascent Biotech Receives One Million Dollar Commitment From TRITON FUNDS LP2019-09-11T12:30:00Z<![CDATA[SAN DIEGO, Calif., Sept. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB:NBIO), a biopharmaceutical company focusing on the development of monoclonal antibodies for the treatment of various types of cancers, announces an agreement with TRITON FUNDS LP. TRITON FUNDS LP will invest $1 million to support the commencement of Phase I human clinical studies on Nascent’s primary asset, Pritumumab.]]>https://www.globenewswire.com/news-release/2019/08/19/1903716/0/en/Nascent-Biotech-Has-Entered-into-an-Agreement-to-Perform-Phase-I-Clinical-Study-for-Brain-Cancer.html?f=22&fvtc=4&fvtv=52156Nascent Biotech Has Entered into an Agreement to Perform Phase I Clinical Study for Brain Cancer2019-08-19T18:04:19Z<![CDATA[Study Planned for Multiple Brain Cancer Types in Phase I Setting]]>https://www.globenewswire.com/news-release/2019/06/05/1864666/0/en/Nascent-Biotech-Officers-Convert-Liability-to-Stock-in-the-Company.html?f=22&fvtc=4&fvtv=52156Nascent Biotech Officers Convert Liability to Stock in the Company2019-06-05T13:00:00Z<![CDATA[San Diego, CA, June 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTC: NBIO) announced today that two of its Senior Officers have converted the Company’s liability to them to common stock.]]>https://www.globenewswire.com/news-release/2019/05/09/1820740/0/en/Nascent-Biotech-Founder-Dr-Mark-Glassy-Will-Present-at-AAI-Convention-in-San-Diego.html?f=22&fvtc=4&fvtv=52156Nascent Biotech Founder, Dr. Mark Glassy, Will Present at AAI Convention in San Diego2019-05-09T12:30:00Z<![CDATA[SAN DIEGO, CA, May 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO) founder Dr. Mark C. Glassy will present an abstract on a natural human lgG1 mAb, Pritumumab, which targets cell surface expressed vimentin and inhibits tumor growth, at the AAI convention this week in San Diego, California.]]>https://www.globenewswire.com/news-release/2019/04/09/1799945/0/en/Nascent-Biotech-Moves-Corporate-Offices-to-San-Diego.html?f=22&fvtc=4&fvtv=52156Nascent Biotech Moves Corporate Offices to San Diego2019-04-09T16:53:25Z<![CDATA[San Diego, CA, April 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO) has moved their corporate offices to San Diego, CA.]]>https://www.globenewswire.com/news-release/2018/12/11/1665087/0/en/Nascent-Biotech-Receives-Clearance-From-FDA-to-Begin-Phase-I-Human-Trials-in-Brain-Cancer.html?f=22&fvtc=4&fvtv=52156Nascent Biotech Receives Clearance From FDA to Begin Phase I Human Trials in Brain Cancer2018-12-11T13:00:00Z<![CDATA[Vero Beach, FL, Dec. 11, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTC: NBIO) received US Food and Drug Administration (FDA) Clearance to begin Phase 1 Clinical Trials effective December 7th, 2018.]]>